Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy

Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to va...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2018-01, Vol.217 (3), p.494-497
Main Authors: Sicre de Fontbrune, Flore, Arnaud, Cécile, Cheminant, Morgane, Boulay, Aude, Konopacki, Johana, Lapusan, Simona, Robin, Christine, Bernaudin, Françoise, Suarez, Felipe, Simon, François, Socié, Gérard, Colin de Verdière, Nathalie, Consigny, Paul-Henri
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3
cites cdi_FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3
container_end_page 497
container_issue 3
container_start_page 494
container_title The Journal of infectious diseases
container_volume 217
creator Sicre de Fontbrune, Flore
Arnaud, Cécile
Cheminant, Morgane
Boulay, Aude
Konopacki, Johana
Lapusan, Simona
Robin, Christine
Bernaudin, Françoise
Suarez, Felipe
Simon, François
Socié, Gérard
Colin de Verdière, Nathalie
Consigny, Paul-Henri
description Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to vaccination. Abstract As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.
doi_str_mv 10.1093/infdis/jix564
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1958537788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jix564</oup_id><sourcerecordid>1958537788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3</originalsourceid><addsrcrecordid>eNqFUU1v1DAQtRCILoUjV-Qjl1DbWSfOcbWitFIlJLq04hTN2hPqKrGN7bTsb-mfxVUKHHuaD715b2YeIe85-8RZV59YNxibTm7tb9msX5AVl3VbNQ2vX5IVY0JUXHXdEXmT0i1jbF037WtyJDqmWinYijycT9Ps_E90Vtt8oOAMvYQBS-oH-gPH0d_TU7zDSK9Aa-uQWkc3pV1G0Gp6hhNkH7zFXKrLjBPdlim6i-BSGMFl-g21DRZdTnQz5MJ0bfONiXAP46PIskGaQ4iYkr1DurvBCOHwlrwaYEz47ikek--nn3fbs-ri65fz7eai0nUjcwVqz9pWGmkMMAECG75vRL1uUAiOotPAQTGmuOBStUauOWo0ewSNuu441Mfk48Ibov81Y8r9ZJMuR4BDP6eed1KVr7ZKFWi1QHX0KUUc-hDtBPHQc9Y_-tEvfvSLHwX_4Yl63k9o_qH_GvBf28_hGa4_jzyaSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1958537788</pqid></control><display><type>article</type><title>Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy</title><source>Oxford Journals Online</source><creator>Sicre de Fontbrune, Flore ; Arnaud, Cécile ; Cheminant, Morgane ; Boulay, Aude ; Konopacki, Johana ; Lapusan, Simona ; Robin, Christine ; Bernaudin, Françoise ; Suarez, Felipe ; Simon, François ; Socié, Gérard ; Colin de Verdière, Nathalie ; Consigny, Paul-Henri</creator><creatorcontrib>Sicre de Fontbrune, Flore ; Arnaud, Cécile ; Cheminant, Morgane ; Boulay, Aude ; Konopacki, Johana ; Lapusan, Simona ; Robin, Christine ; Bernaudin, Françoise ; Suarez, Felipe ; Simon, François ; Socié, Gérard ; Colin de Verdière, Nathalie ; Consigny, Paul-Henri</creatorcontrib><description>Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to vaccination. Abstract As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jix564</identifier><identifier>PMID: 29087520</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>The Journal of infectious diseases, 2018-01, Vol.217 (3), p.494-497</ispartof><rights>The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2017</rights><rights>The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3</citedby><cites>FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29087520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sicre de Fontbrune, Flore</creatorcontrib><creatorcontrib>Arnaud, Cécile</creatorcontrib><creatorcontrib>Cheminant, Morgane</creatorcontrib><creatorcontrib>Boulay, Aude</creatorcontrib><creatorcontrib>Konopacki, Johana</creatorcontrib><creatorcontrib>Lapusan, Simona</creatorcontrib><creatorcontrib>Robin, Christine</creatorcontrib><creatorcontrib>Bernaudin, Françoise</creatorcontrib><creatorcontrib>Suarez, Felipe</creatorcontrib><creatorcontrib>Simon, François</creatorcontrib><creatorcontrib>Socié, Gérard</creatorcontrib><creatorcontrib>Colin de Verdière, Nathalie</creatorcontrib><creatorcontrib>Consigny, Paul-Henri</creatorcontrib><title>Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to vaccination. Abstract As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.</description><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFUU1v1DAQtRCILoUjV-Qjl1DbWSfOcbWitFIlJLq04hTN2hPqKrGN7bTsb-mfxVUKHHuaD715b2YeIe85-8RZV59YNxibTm7tb9msX5AVl3VbNQ2vX5IVY0JUXHXdEXmT0i1jbF037WtyJDqmWinYijycT9Ps_E90Vtt8oOAMvYQBS-oH-gPH0d_TU7zDSK9Aa-uQWkc3pV1G0Gp6hhNkH7zFXKrLjBPdlim6i-BSGMFl-g21DRZdTnQz5MJ0bfONiXAP46PIskGaQ4iYkr1DurvBCOHwlrwaYEz47ikek--nn3fbs-ri65fz7eai0nUjcwVqz9pWGmkMMAECG75vRL1uUAiOotPAQTGmuOBStUauOWo0ewSNuu441Mfk48Ibov81Y8r9ZJMuR4BDP6eed1KVr7ZKFWi1QHX0KUUc-hDtBPHQc9Y_-tEvfvSLHwX_4Yl63k9o_qH_GvBf28_hGa4_jzyaSQ</recordid><startdate>20180117</startdate><enddate>20180117</enddate><creator>Sicre de Fontbrune, Flore</creator><creator>Arnaud, Cécile</creator><creator>Cheminant, Morgane</creator><creator>Boulay, Aude</creator><creator>Konopacki, Johana</creator><creator>Lapusan, Simona</creator><creator>Robin, Christine</creator><creator>Bernaudin, Françoise</creator><creator>Suarez, Felipe</creator><creator>Simon, François</creator><creator>Socié, Gérard</creator><creator>Colin de Verdière, Nathalie</creator><creator>Consigny, Paul-Henri</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180117</creationdate><title>Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy</title><author>Sicre de Fontbrune, Flore ; Arnaud, Cécile ; Cheminant, Morgane ; Boulay, Aude ; Konopacki, Johana ; Lapusan, Simona ; Robin, Christine ; Bernaudin, Françoise ; Suarez, Felipe ; Simon, François ; Socié, Gérard ; Colin de Verdière, Nathalie ; Consigny, Paul-Henri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sicre de Fontbrune, Flore</creatorcontrib><creatorcontrib>Arnaud, Cécile</creatorcontrib><creatorcontrib>Cheminant, Morgane</creatorcontrib><creatorcontrib>Boulay, Aude</creatorcontrib><creatorcontrib>Konopacki, Johana</creatorcontrib><creatorcontrib>Lapusan, Simona</creatorcontrib><creatorcontrib>Robin, Christine</creatorcontrib><creatorcontrib>Bernaudin, Françoise</creatorcontrib><creatorcontrib>Suarez, Felipe</creatorcontrib><creatorcontrib>Simon, François</creatorcontrib><creatorcontrib>Socié, Gérard</creatorcontrib><creatorcontrib>Colin de Verdière, Nathalie</creatorcontrib><creatorcontrib>Consigny, Paul-Henri</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sicre de Fontbrune, Flore</au><au>Arnaud, Cécile</au><au>Cheminant, Morgane</au><au>Boulay, Aude</au><au>Konopacki, Johana</au><au>Lapusan, Simona</au><au>Robin, Christine</au><au>Bernaudin, Françoise</au><au>Suarez, Felipe</au><au>Simon, François</au><au>Socié, Gérard</au><au>Colin de Verdière, Nathalie</au><au>Consigny, Paul-Henri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2018-01-17</date><risdate>2018</risdate><volume>217</volume><issue>3</issue><spage>494</spage><epage>497</epage><pages>494-497</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to vaccination. Abstract As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>29087520</pmid><doi>10.1093/infdis/jix564</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 2018-01, Vol.217 (3), p.494-497
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_1958537788
source Oxford Journals Online
title Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A32%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20Safety%20of%20Yellow%20Fever%20Vaccine%20in%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant%20Recipients%20After%20Withdrawal%20of%20Immunosuppressive%20Therapy&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Sicre%20de%20Fontbrune,%20Flore&rft.date=2018-01-17&rft.volume=217&rft.issue=3&rft.spage=494&rft.epage=497&rft.pages=494-497&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jix564&rft_dat=%3Cproquest_cross%3E1958537788%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-a8b0775d5dda02a2e61b62346e221e29ca1a8008121587d541ecedbeacec391a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1958537788&rft_id=info:pmid/29087520&rft_oup_id=10.1093/infdis/jix564&rfr_iscdi=true